Incidence of Cardiovascular Events and Extrahepatic Malignancies in Steatotic Liver Disease Subgroups
- 2 June 2026
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (10) , 1-10
Abstract
Purpose People with metabolic dysfunction-associated steatotic liver disease (MASLD) or alcohol-related liver disease (ALD) are at increased risk of cardiovascular (CV) events and extrahepatic cancers. However, data on MASLD with increased alcohol intake (MetALD) are limited. We investigated the incidence of CV events and extrahepatic cancers across SLD subgroups. Methods Patients with histologically confirmed SLD were included. Incident CV events (heart failure, ischemic heart disease (IHD), cerebrovascular disease, peripheral vascular disease) and extrahepatic cancers were recorded. Five-year cumulative incidence and sHR were estimated using competing risk regression with death and transplantation as competing events. Results 739 patients were included: 525 (71%) MASLD, 88 (12%) MetALD and 126 (17%) ALD. Mean age was 51 ± 13 years and 63% were male. Advanced fibrosis (F ≥ 3) was present in 39%. Over a median follow-up of 6.3 (IQR 3.8–8.3) years, 75 (10.1%) patients died, and 60 incident CV events occurred, most commonly IHD (46.6%). Estimated five-year cumulative incidence of CV events was 5.3% in MASLD, 7.4% in MetALD and 3.2% in ALD. Extrahepatic cancers occurred in 55 patients, most frequently skin and prostate. Estimated five-year cumulative incidence of extrahepatic cancers was 3.4% in MASLD, 4.9% in MetALD and 4.3% in ALD. The SLD subgroup was not independently associated with CV events, but MetALD (sHR 2.43, p = 0.021) and ALD (sHR 1.96, p = 0.040) were independently associated with extrahepatic cancer risk. Conclusions In this cohort of biopsy-proven SLD, the risk of extrahepatic cancer was higher in patients with MetALD. These findings may reflect synergistic effects of metabolic risk and alcohol exposure.Keywords
This publication has 43 references indexed in Scilit:
- Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver DiseaseJAMA Internal Medicine, 2025
- Incidence and predictors of non-hepatic cancers in biopsy-proven alcohol-related liver diseaseAnnals of Hepatology, 2025
- You can't handle the truth! Comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patientsDigestive and Liver Disease, 2024
- Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017–2020Clinical Gastroenterology and Hepatology, 2023
- Cardiovascular Outcomes in Patients With Biopsy-proven Alcohol-related Liver DiseaseClinical Gastroenterology and Hepatology, 2022
- Baseline and lifetime alcohol consumption and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC)International Journal of Cancer, 2022
- Risk of cardiovascular disease and loss in life expectancy in NAFLDHepatology, 2022
- Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general populationHepatology, 2017
- Practical recommendations for reportingFine‐Gray model analyses for competing risk dataStatistics in Medicine, 2017
- Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §ΔHepatology, 2010